Abstract: A method for treating and/or delaying the degeneration of Purkinje cells in a subject is provided. The method comprises administering to a subject in need thereof a therapeutically effective amount of a medicament, wherein the medicament comprises a phthalide selected from the group consisting of n-butylidenephthalide (BP), a metabolic precursor of BP, a pharmaceutically acceptable salt of a metabolic precursor of BP, a pharmaceutically acceptable ester of a metabolic precursor of BP, and combinations thereof.

Abstract: A method for treating pancreatic cancer is provided. The method comprises administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical formulation, wherein the pharmaceutical formulation comprises (Z)-butylidenephthalide and is substantially free of (E)-butylidenephthalide.

Abstract: A method for at least one of activating autoimmune system and treating cancer is provided. The method comprises administering to a subject in need an effective amount of Z-butylidenephthalide and an effective amount of monocytes.

Abstract: The present invention relates to a method of delaying the onset of pulmonary fibrosis or treating pulmonary fibrosis, comprising administering to a subject in need an effective amount of an active ingredient selected from the group consisting of a compound of formula (I), a pharmaceutically acceptable salt of the compound of formula (I), and combinations thereof: wherein, A is a C5 alkyl or alkenyl optionally substituted with —OH or ?O; X is H or OH; Y is O; and R1 is H or absent, with the proviso that, when R1 is absent, Y and A bind together to form a five-membered ring.

Abstract: A method for the anti-senescence of and/or rejuvenating a stem cell is provided. The method comprising treating the stem cell with trans-cinnamaldehyde (TC). A kit is also provided. The kit comprising (1) a first part, comprising a stem cell; (2) a second part, comprising TC; and (3) a culture medium of the stem cell, placed in at least one of the first part, the second part, and a third part. In addition, a method for stem cell therapy is provided. The method comprising administering to a subject in need an effective amount of a stem cell, wherein the stem cell has been treated with TC before being administered.

Abstract: This invention relates to a pharmaceutical formulation containing z-butylidenephthalide and a polymer, e.g., a polyanhydride. Also disclosed is use of this formulation to treat tumor.

Abstract: A method for preventing, mitigating and/or inhibiting the growth, migration, invasion and/or metastasis of cancer stem cell (CSC) is provided. The method comprises administering to a subject in need an effective amount of butylidenephthalide (BP).

Abstract: A pharmaceutical composition comprising: (a) a medium system, comprising a first component, a second component and a third component, wherein the first component is a phosphate buffered saline, the second component is selected from the group consisting of vegetable oils, animal oils, fatty acids and combinations thereof, and the third component is selected from the group consisting of polyethylene glycol, dimethyl sulfoxide (DMSO), ethanol, polypropylene glycol, polysorbate, polyoxyethylated vegetable oil, ethyl acetate, 2-hydroxyethyl 12-hydroxyoctadecanoate, tocopheryl polyethylene glycol succinate and combinations thereof; and (b) n-butylidenephthalide (BP).

Abstract: A method for providing an increased expression of at least one of telomerase, brain-derived neurotrophic factor (BDNF), stromal cell-derived factor-1 (SDF1), CXC chemokine receptor 4 (CXCR4), and an immune regulatory factor of a stem cell in a subject is provided. The method comprises simultaneously or separately administering to the subject an effective amount of (a) a phthalide and (b) a stem cell.

Abstract: A method for the anti-senescence of and/or rejuvenating a stem cell is provided. The method comprising treating the stem cell with trans-cinnamaldehyde (TC). A kit is also provided. The kit comprising (1) a first part, comprising a stem cell; (2) a second part, comprising TC; and (3) a culture medium of the stem cell, placed in at least one of the first part, the second part, and a third part. In addition, a method for stem cell therapy is provided. The method comprising administering to a subject in need an effective amount of a stem cell, wherein the stem cell has been treated with TC before being administered.

Abstract: A method for treating and/or delaying the degeneration of Purkinje cells in a subject is provided. The method comprises administering to a subject in need thereof a therapeutically effective amount of a medicament, wherein the medicament comprises a phthalide selected from the group consisting of n-butylidenephthalide (BP), a metabolic precursor of BP, a pharmaceutically acceptable salt of a metabolic precursor of BP, a pharmaceutically acceptable ester of a metabolic precursor of BP, and combinations thereof.

Abstract: A method for treating pancreatic cancer is provided. The method comprises administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical formulation, wherein the pharmaceutical formulation comprises (Z)-butylidenephthalide and is substantially free of (E)-butylidenephthalide.

Abstract: A pharmaceutical composition comprising: (a) a medium system, comprising a first component, a second component and a third component, wherein the first component is a phosphate buffered saline, the second component is selected from the group consisting of vegetable oils, animal oils, fatty acids and combinations thereof, and the third component is selected from the group consisting of polyethylene glycol, dimethyl sulfoxide (DMSO), ethanol, polypropylene glycol, polysorbate, polyoxyethylated vegetable oil, ethyl acetate, 2-hydroxyethyl 12-hydroxyoctadecanoate, tocopheryl polyethylene glycol succinate and combinations thereof; and (b) n-butylidenephthalide (BP).

Abstract: A mesenchymal stem cell extract and its use are provided, wherein the mesenchymal stem cell extract comprises a trophic factor(s), such as bone morphogenetic protein-7 (BMP-7), stromal cell-derived factor-1 (SDF-1), vascular endothelial growth factor (VEGF), C-X-C chemokine receptor type-4 (CXCR4), brain-derived neurotrophic factor (BDNF), and/or interleukin-17 (IL-17), and wherein the extract is especially suitable for repairing skin aging.

Abstract: This invention relates to a pharmaceutical formulation containing z-butylidenephthalide and a polymer, e.g., a polyanhydride. Also disclosed is use of this formulation to treat tumor.

Abstract: A method for improving skin appearance and/or reducing hair loss in a subject is provided. The method comprises administrating to the subject an effective amount of peripheral monocytes, wherein the peripheral monocytes are induced by granulocyte colony stimulating factor (GCSF) or a combination of GCSF and an interleukin relative to GCSF.

Abstract: Provided is a method for treating brain cancer or reducing temozolomide-resistance of brain cancer cells in a subject, comprising administrating to the subject an effective amount of an active ingredient selected from the group consisting of (Z)-butylidenephthalide of formula (I), a pharmaceutically acceptable salt of (Z)-butylidenephthalide, a pharmaceutically acceptable ester of (Z)-butylidenephthalide, and combinations thereof:

Abstract: Provided is a method for treating a liver injury such as fibrosis, cirrhosis and hepatitis as well as a method for restoring liver function in a subject, which includes administrating to the subject a therapeutically effective amount of n-butylidenephthalide having the formula (I) as an active ingredient, or a pharmaceutically acceptable salt of ester thereof: wherein R is ?CHCH2CH2CH3, and n-butylidenephthalide (I) is E form, Z form or a mixture thereof.

Abstract: A method for providing an increased expression of at least one of telomerase, brain-derived neurotrophic factor (BDNF), stromal cell-derived factor-1 (SDF1), CXC chemokine receptor 4 (CXCR4), and an immune regulatory factor of a stem cell in a subject is provided. The method comprises simultaneously or separately administering to the subject an effective amount of (a) a phthalide and (b) a stem cell.

Abstract: A method for inhibiting the autophagy of motor neurons in a subject is provided. The method comprises administrating to the subject an effective amount of an active ingredient selected from the group consisting of a compound of formula (I), a pharmaceutically acceptable salt of the compound, a pharmaceutically acceptable ester of the compound and combinations thereof: wherein A is a C1-C5 alkyl optionally having one or more unsaturated bonds and optionally being substituted by one or more substituents selected from a group consisting of —OH, ?O and C1-C3 alkyl; X is H, —OH, Y is O or S and can optionally combine with A to form a five-membered ring; and R1 is H or a substituted or unsubstituted C1-C20 alkyl, wherein one or more —CH2— of the C1-C20 alkyl are optionally being replaced by —NH— or —O—.